<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35975404</PMID><DateCompleted><Year>2022</Year><Month>12</Month><Day>05</Day></DateCompleted><DateRevised><Year>2023</Year><Month>04</Month><Day>11</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1365-2982</ISSN><JournalIssue CitedMedium="Internet"><Volume>34</Volume><Issue>12</Issue><PubDate><Year>2022</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Neurogastroenterology and motility</Title><ISOAbbreviation>Neurogastroenterol Motil</ISOAbbreviation></Journal><ArticleTitle>Efficacy and safety of vibegron for the treatment of irritable bowel syndrome in women: Results of a randomized, double-blind, placebo-controlled phase 2 trial.</ArticleTitle><Pagination><StartPage>e14448</StartPage><MedlinePgn>e14448</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e14448</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1111/nmo.14448</ELocationID><Abstract><AbstractText Label="BACKGROUND">Preclinical and clinical studies suggest that &#x3b2;<sub>3</sub> -adrenergic receptor activation may be a novel target for treating abdominal pain and gastrointestinal motility dysfunction in patients with irritable bowel syndrome (IBS). This proof-of-concept study evaluated the efficacy and safety of the &#x3b2;<sub>3</sub> -adrenergic agonist vibegron in treating IBS-related pain.</AbstractText><AbstractText Label="METHODS">Adult women with predominant-diarrhea IBS (IBS-D) or with mixed diarrhea/constipation (IBS-M), diagnosed using Rome IV criteria, were randomized 1:1 to receive once-daily vibegron 75&#xa0;mg or placebo for 12&#xa0;weeks. The primary endpoint was the percentage of patients with IBS-D considered abdominal pain intensity (API) weekly responders, defined as &#x2265;30% reduction from baseline at week 12 in mean weekly worst abdominal pain over 24&#xa0;hours using the API score. Patients completed a pain diary at baseline and at weeks 2, 4, 8, and 12. Safety was assessed by adverse events (AEs) in the overall IBS population.</AbstractText><AbstractText Label="KEY RESULTS">Of the 222 patients with IBS randomized (vibegron, N&#xa0;=&#xa0;111; placebo, N&#xa0;=&#xa0;111), 85% completed the trial. There was no significant difference in the percentage of patients with IBS-D (vibegron, N&#xa0;=&#xa0;66; placebo, N&#xa0;=&#xa0;63) considered API weekly responders with vibegron vs. placebo (p&#xa0;=&#xa0;0.8222) after 12&#xa0;weeks. The incidence of AEs was comparable between treatment groups (33.3% each), with equal rates of worsening IBS symptoms (2.7% each).</AbstractText><AbstractText Label="CONCLUSIONS AND INFERENCES">In women with IBS-D, vibegron was not associated with significant improvement in the percentage of API weekly responders. Vibegron was generally safe and well tolerated and, in particular, did not worsen IBS symptoms vs. placebo.</AbstractText><CopyrightInformation>&#xa9; 2022 The Authors. Neurogastroenterology &amp; Motility published by John Wiley &amp; Sons Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lacy</LastName><ForeName>Brian E</ForeName><Initials>BE</Initials><Identifier Source="ORCID">0000-0002-2778-0786</Identifier><AffiliationInfo><Affiliation>Gastroenterology and Hepatology, Mayo Clinic, Jacksonville, Florida, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>King</LastName><ForeName>Jennifer</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Urovant Sciences, Irvine, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shortino</LastName><ForeName>Denise</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Urovant Sciences, Irvine, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schaumburg</LastName><ForeName>Chris</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Urovant Sciences, Irvine, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Haag-Molkenteller</LastName><ForeName>Cornelia</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Urovant Sciences, Irvine, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chey</LastName><ForeName>William D</ForeName><Initials>WD</Initials><AffiliationInfo><Affiliation>Division of Gastroenterology, University of Michigan Health System, Ann Arbor, Michigan, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D017427">Clinical Trial, Phase II</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>08</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Neurogastroenterol Motil</MedlineTA><NlmUniqueID>9432572</NlmUniqueID><ISSNLinking>1350-1925</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D043183" MajorTopicYN="Y">Irritable Bowel Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003248" MajorTopicYN="N">Constipation</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003967" MajorTopicYN="N">Diarrhea</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015746" MajorTopicYN="N">Abdominal Pain</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">abdominal pain</Keyword><Keyword MajorTopicYN="N">constipation</Keyword><Keyword MajorTopicYN="N">diarrhea</Keyword><Keyword MajorTopicYN="N">functional colonic diseases</Keyword><Keyword MajorTopicYN="N">gastrointestinal diseases</Keyword><Keyword MajorTopicYN="N">irritable bowel syndrome</Keyword></KeywordList><CoiStatement>
<b>BE Lacy</b> is a consultant and/or on the scientific advisory boards for Allakos, Alpha Sigma, Arena Pharmaceuticals, Ironwood, Salix, Sanofi, and Viver and serves on the Rome Board of Directors. <b>J King</b>, <b>D Shortino, C Schaumburg</b>, and <b>C Haag&#x2010;Molkenteller</b> were employees of Urovant Sciences at the time the work was conducted. <b>WD Chey</b> is a consultant for Abbvie, Allakos, Alnylam, Arena, Bayer, Biomerica, Ironwood, Nestle, QOL Medical, Salix/Valeant, Takeda, Urovant Sciences, and Vibrant; has received grant and/or research study funding from Biomerica, Commonwealth Diagnostics International, QOL Medical, and Salix; has stock options in GI on Demand, Modify Health, and Ritter; serves on the Rome Board of Directors; and is a member of the Board of Trustees of the American College of Gastroenterology and Board of Directors of the International Foundation for Gastrointestinal Disorders.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>5</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>12</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>7</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>8</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>12</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>8</Month><Day>17</Day><Hour>3</Hour><Minute>2</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>4</Month><Day>6</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35975404</ArticleId><ArticleId IdType="pmc">PMC10078113</ArticleId><ArticleId IdType="doi">10.1111/nmo.14448</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Sperber AD, Bangdiwala SI, Drossman DA, et al. Worldwide prevalence and burden of functional gastrointestinal disorders, results of Rome foundation global study. Gastroenterology. 2021;160:99&#x2010;114.</Citation><ArticleIdList><ArticleId IdType="pubmed">32294476</ArticleId></ArticleIdList></Reference><Reference><Citation>Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC. Functional bowel disorders. Gastroenterology. 2006;130:1480&#x2010;1491.</Citation><ArticleIdList><ArticleId IdType="pubmed">16678561</ArticleId></ArticleIdList></Reference><Reference><Citation>Chey WD, Kurlander J, Eswaran S. Irritable bowel syndrome: a clinical review. Jama. 2015;313:949&#x2010;958.</Citation><ArticleIdList><ArticleId IdType="pubmed">25734736</ArticleId></ArticleIdList></Reference><Reference><Citation>Lacy BE, Mearin F, Chang L, et al. Bowel disorders. Gastroenterology. 2016;150:1393&#x2010;1407.</Citation><ArticleIdList><ArticleId IdType="pubmed">27144627</ArticleId></ArticleIdList></Reference><Reference><Citation>Ford AC, Moayyedi P, Chey WD, et al. American College of Gastroenterology monograph on management of irritable bowel syndrome. Am J Gastroenterol. 2018;113:1&#x2010;18.</Citation><ArticleIdList><ArticleId IdType="pubmed">29950604</ArticleId></ArticleIdList></Reference><Reference><Citation>Lacy BE, Pimentel M, Brenner DM, et al. ACG clinical guideline: management of irritable bowel syndrome. Am J Gastroenterol. 2021;116:17&#x2010;44.</Citation><ArticleIdList><ArticleId IdType="pubmed">33315591</ArticleId></ArticleIdList></Reference><Reference><Citation>Palsson OS, Whitehead W, Tornblom H, Sperber AD, Simren M. Prevalence of Rome IV functional bowel disorders among adults in the United States, Canada, and the United Kingdom. Gastroenterology. 2020;158:1262&#x2010;1273.</Citation><ArticleIdList><ArticleId IdType="pubmed">31917991</ArticleId></ArticleIdList></Reference><Reference><Citation>De Ponti F, Gibelli G, Croci T, Arcidiaco M, Crema F, Manara L. Functional evidence of atypical beta 3&#x2010;adrenoceptors in the human colon using the beta 3&#x2010;selective adrenoceptor antagonist, SR 59230A. Br J Pharmacol. 1996;117:1374&#x2010;1376.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1909449</ArticleId><ArticleId IdType="pubmed">8730727</ArticleId></ArticleIdList></Reference><Reference><Citation>Krief S, Lonnqvist F, Raimbault S, et al. Tissue distribution of beta 3&#x2010;adrenergic receptor mRNA in man. J Clin Invest. 1993;91:344&#x2010;349.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC330032</ArticleId><ArticleId IdType="pubmed">8380813</ArticleId></ArticleIdList></Reference><Reference><Citation>Cellek S, Thangiah R, Bassil AK, et al. Demonstration of functional neuronal beta3&#x2010;adrenoceptors within the enteric nervous system. Gastroenterology. 2007;133:175&#x2010;183.</Citation><ArticleIdList><ArticleId IdType="pubmed">17631141</ArticleId></ArticleIdList></Reference><Reference><Citation>Grudell AB, Camilleri M, Jensen KL, et al. Dose&#x2010;response effect of a beta3&#x2010;adrenergic receptor agonist, solabegron, on gastrointestinal transit, bowel function, and somatostatin levels in health. Am J Physiol Gastrointest Liver Physiol. 2008;294:G1114&#x2010;G1119.</Citation><ArticleIdList><ArticleId IdType="pubmed">18372395</ArticleId></ArticleIdList></Reference><Reference><Citation>Kelleher DL, Hicks KJ, Cox DS, Williamson RR, Alpers DH, Dukes GE. Randomized, double&#x2010;blind, placebo (PLA)&#x2010;controlled, crossover study to evaluate efficacy and safety of the beta 3&#x2010;adrenergic receptor agonist solabegron (SOL) in patients with irritable bowel syndrome (IBS). Neurogastroenterol Motil. 2008;20:131&#x2010;132.</Citation></Reference><Reference><Citation>Brucker BM, McHale K, King J, Mudd PN. Selectivity and maximum response of vibegron and mirabegron for &#x3b2;3&#x2010;adrenergic receptors. Society of Urodynamics, Female Pelvic Medicine and Urogenital Reconstruction 2021 Winter Meeting; 2021 February 25&#x2010;27; Virtual Congress</Citation></Reference><Reference><Citation>Urovant Sciences, Inc. GEMTESA&#xae; (vibegron) . Full Prescribing Information: Urovant Sciences, Inc: 2020.</Citation></Reference><Reference><Citation>Staskin D, Frankel J, Varano S, Shortino D, Jankowich R, Mudd PN Jr. International phase III, randomized, double&#x2010;blind, placebo and active controlled study to evaluate the safety and efficacy of vibegron in patients with symptoms of overactive bladder: EMPOWUR. J Urol. 2020;204:316&#x2010;324.</Citation><ArticleIdList><ArticleId IdType="pubmed">32068484</ArticleId></ArticleIdList></Reference><Reference><Citation>Staskin D, Frankel J, Varano S, Shortino D, Jankowich R, Mudd PN Jr. Once&#x2010;daily vibegron 75 mg for overactive bladder: long&#x2010;term safety and efficacy from a double&#x2010;blind extension study of the international phase 3 trial (EMPOWUR). J Urol. 2021;205:1421&#x2010;1429.</Citation><ArticleIdList><ArticleId IdType="pubmed">33356445</ArticleId></ArticleIdList></Reference><Reference><Citation>Gordon S, Ameen V, Bagby B, Shahan B, Jhingran P, Carter E. Validation of irritable bowel syndrome global improvement scale: an integrated symptom end point for assessing treatment efficacy. Dig Dis Sci. 2003;48:1317&#x2010;1323.</Citation><ArticleIdList><ArticleId IdType="pubmed">12870789</ArticleId></ArticleIdList></Reference><Reference><Citation>Lembo T, Wright RA, Bagby B, et al. Alosetron controls bowel urgency and provides global symptom improvement in women with diarrhea&#x2010;predominant irritable bowel syndrome. Am J Gastroenterol. 2001;96:2662&#x2010;2670.</Citation><ArticleIdList><ArticleId IdType="pubmed">11569692</ArticleId></ArticleIdList></Reference><Reference><Citation>Greenland S, Robins JM. Estimation of a common effect parameter from sparse follow&#x2010;up data. Biometrics. 1985;41:55&#x2010;68.</Citation><ArticleIdList><ArticleId IdType="pubmed">4005387</ArticleId></ArticleIdList></Reference><Reference><Citation>Mangel AW, Wang J, Sherrill B, Gnanasakthy A, Ervin C, Fehnel SE. Urgency as an endpoint in irritable bowel syndrome. Gastroenterology Res. 2011;4:9&#x2010;12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5139794</ArticleId><ArticleId IdType="pubmed">27957006</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsumoto S, Hashizume K, Wada N, et al. Relationship between overactive bladder and irritable bowel syndrome: a large&#x2010;scale internet survey in Japan using the overactive bladder symptom score and Rome III criteria. BJU Int. 2013;111:647&#x2010;652.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3654175</ArticleId><ArticleId IdType="pubmed">23106867</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsuzaki J, Suzuki H, Fukushima Y, et al. High frequency of overlap between functional dyspepsia and overactive bladder. Neurogastroenterol Motil. 2012;24:821&#x2010;827.</Citation><ArticleIdList><ArticleId IdType="pubmed">22616664</ArticleId></ArticleIdList></Reference><Reference><Citation>Rusu F, Dumitrascu DL. Four years follow&#x2010;up of patients with irritable bowel syndrome. Rom J Intern Med. 2015;53:63&#x2010;72.</Citation><ArticleIdList><ArticleId IdType="pubmed">26076563</ArticleId></ArticleIdList></Reference><Reference><Citation>Talley NJ. Pharmacologic therapy for the irritable bowel syndrome. Am J Gastroenterol. 2003;98:750&#x2010;758.</Citation><ArticleIdList><ArticleId IdType="pubmed">12738451</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>